Moderna, Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Moderna, Inc. stock analysis MRNA overview
Slightly Bullish +25

Stock Traders Purchase Large Volume of Moderna Call Options (NASDAQ:MRNA) - MarketBeat

📈 Traders purchased 113,636 call options on Moderna, a 47% increase over average volume indicating bullish sentiment.

💰 Revenue of $678M beat analyst expectations of $611M but fell 33.2% year-over-year.

📉 EPS of -$2.11 beat the consensus estimate of -$2.79, though the company remains unprofitable.

👔 President Stephen Hoge sold 160,009 shares at $48.84, reducing his stake by 9.89%.

🏦 Institutional ownership stands at 75.33%, with insiders holding 10.8% of the company's stock.

📊 Analyst consensus rating is 'Reduce' with a target price of $32.33, below current trading levels.

🔍 BMO Capital Markets upgraded Moderna to 'buy', while Piper Sandler increased its price objective to $69.

📉 Stock traded down $4.01 to $49.56 with volume of 7.08 million shares on Friday.

📅 Analysts expect -$9.61 EPS for the current year, highlighting continued profitability challenges.

🧬 Moderna specializes in mRNA therapeutics and vaccines, with a pipeline targeting infectious diseases and genetic disorders.

Bullish Signals
  • Call option volume surged by 47% to 113,636 shares, signaling strong bullish interest from traders.
  • Quarterly EPS of -$2.11 exceeded analyst expectations of -$2.79, demonstrating improved operational performance.
  • Revenue of $678M surpassed the consensus estimate of $611M, showing resilience despite market headwinds.
  • BMO Capital Markets upgraded the stock from 'market perform' to 'buy', reflecting positive analyst sentiment.
  • Piper Sandler increased its price objective to $69 and maintained an 'overweight' rating on the company.
  • The company maintains a strong balance sheet with a debt-to-equity ratio of only 0.07.
Risk Factors
  • Revenue declined by 33.2% year-over-year, indicating a significant contraction in business activity.
  • The company remains unprofitable with a negative return on equity of 30.15% and negative net margin.
  • Analyst consensus rating is 'Reduce' with a target price of $32.33, suggesting limited near-term upside.
  • President Stephen Hoge sold nearly 10% of his stake, potentially signaling insider concerns about valuation.
  • Analysts expect -$9.61 EPS for the current year, highlighting ongoing profitability challenges.
Full Analysis
Moderna (NASDAQ:MRNA) saw unusual bullish activity as traders purchased 113,636 call options on Friday, representing a 47% increase over the average volume. Despite this positive options flow, the stock traded down $4.01 to reach $49.56 during mid-day trading, with volume at 7.08 million shares compared to an average of 11.32 million shares. The company recently reported quarterly earnings that beat expectations on a per-share basis, posting EPS of -$2.11 versus the consensus estimate of -$2.79. Revenue came in at $678 million, exceeding analyst expectations of $611 million, though it represented a significant 33.2% year-over-year decline. The company remains unprofitable with a negative return on equity of 30.15% and a negative net margin of 145.16%. Insider activity highlighted President Stephen Hoge's sale of 160,009 shares at an average price of $48.84, reducing his stake by 9.89%. While insiders still own 10.8% of the stock and institutions hold 75.33%, analyst sentiment remains cautious with a consensus rating of 'Reduce' and a target price of $32.33. Recent analyst actions include upgrades from BMO Capital Markets and Piper Sandler, alongside new coverage from Barclays. Financial metrics show Moderna has a market cap of $19.57 billion, a debt-to-equity ratio of 0.07, and a beta of 1.29. The stock's 50-day moving average is $48.51, while the 200-day moving average sits at $34.95. Analysts expect EPS of -9.61 for the current year, reflecting ongoing challenges in transitioning from pandemic-era revenue to sustainable profitability.